143 related articles for article (PubMed ID: 25057170)
1. Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik.
Delaloge S; Cullell-Young M
Ann Oncol; 2014 Oct; 25(10):2095. PubMed ID: 25057170
[No Abstract] [Full Text] [Related]
2. Treating breast cancer with trabectedin: a new arsenal.
Malik L
Ann Oncol; 2014 Oct; 25(10):2094-2095. PubMed ID: 25057176
[No Abstract] [Full Text] [Related]
3. Trabectedin in ovarian cancer: could we expect more?
Sessa C; D'Incalci M
Ann Oncol; 2011 Jan; 22(1):7-8. PubMed ID: 21059638
[No Abstract] [Full Text] [Related]
4. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin and ovarian cancer (continued).
Prescrire Int; 2011 Oct; 20(120):249-50. PubMed ID: 21970099
[No Abstract] [Full Text] [Related]
6. Trabectedin.
Chuk MK; Balis FM; Fox E
Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
[No Abstract] [Full Text] [Related]
7. Trabectedin and ovarian cancer: statistical trickery.
Prescrire Int; 2011 Apr; 20(115):93. PubMed ID: 21648209
[No Abstract] [Full Text] [Related]
8. Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
Blomqvist C; Johansson R; Tarkkanen M
Ann Oncol; 2011 Apr; 22(4):988. PubMed ID: 21345940
[No Abstract] [Full Text] [Related]
9. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin--a targeted chemotherapy?
von Mehren M
Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
[No Abstract] [Full Text] [Related]
11. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
Reichardt P
Future Oncol; 2015; 11(11 Suppl):1. PubMed ID: 26043309
[No Abstract] [Full Text] [Related]
12. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.
Hollebecque A; Adenis A; Taieb S; Lebedinsky C; Penel N
Invest New Drugs; 2010 Aug; 28(4):529-30. PubMed ID: 19430728
[No Abstract] [Full Text] [Related]
13. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
14. Introduction. Trabectedin treatment in GYN cancers.
Poveda A
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S1-2. PubMed ID: 21540665
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
[TBL] [Abstract][Full Text] [Related]
16. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
Delaloge S; Wolp-Diniz R; Byrski T; Blum JL; Gonçalves A; Campone M; Lardelli P; Kahatt C; Nieto A; Cullell-Young M; Lubinski J
Ann Oncol; 2014 Jun; 25(6):1152-8. PubMed ID: 24692579
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored.
Soini EJ
Ann Oncol; 2011 Jun; 22(6):1465-1466. PubMed ID: 21555363
[No Abstract] [Full Text] [Related]
18. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
19. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
[No Abstract] [Full Text] [Related]
[Next] [New Search]